Practical Research for Innovative Cancer Control Management Office

Fumitaka Takeshita, Satoru Sekiya, Sachie Ishibashi, Takashi Saito, Etsuko Oomichi, Misato Jinno, Tomoko Morita, Yoshiyuki Sano, Kooji Miura, Kiyoshi Inageda, Syooko Ikeda, Toshio Ogawa, Kazuhiko Aoyagi

Introduction

 The "Practical Research for Innovative Cancer Control Management Office (PRIMO)" is one of the research projects of the Innovative Cancer Medical Practical Research Program (Innovative Cancer Program) run by the Japan Agency for Medical Research and Development (AMED). Its main task is to support the Program Supervisor (PS) and Program Officer (PO) of the program, as well as the Principal Investigator (PI) of the Innovative Cancer Program.

Research Activities

1. Support for PS/POs using progress management systems, etc.:

 PRIMO-employed staff (PMs: project mediators) were assigned to each area, and the PRIMO progress management system was used to collect information and prepare reports regarding the progress of assigned projects.

2. Data mining:

 Using the integrated research information database (Dimensions), we worked to enable PS/POs to grasp the overall picture of international cancer research. For macro analysis, we prepared one report as reference material for the "Next 10-Year Cancer Research Strategy," and for micro analysis, we prepared two reports on "Trends in interdisciplinary fusion in cancer research as seen from patent applications" and "Trends in international development of CAR-T therapy."

3. PRIMO consultation:

 With the PM acting as an intermediary, the research team's lead development researchers and co-development researchers provided advice to POs and innovative cancer PIs upon request. "Pharmaceutical consultation" and "Biostatistics" were added to the menu, and 21 consultations were held in FY2013. A research ethics training seminar was held jointly with the Next Generation Cancer Project.

4. PRIMO technical support:

 This is a task to establish collaborations with researchers who can provide bioresources and advanced technologies to the PIs of the Innovative Cancer Project. The technical support menu has been revamped. There were four consultations in FY2023, of which three collaborative research projects were established (two in FY2013).

5. Information dissemination through portal sites, etc.:

 We updated the research and development in the field of cancer supported by AMED as appropriate and posted the data mining reports submitted to AMED. At the 82nd Annual Meeting of the Japanese Cancer Association, we held a luncheon seminar in collaboration with the Next Generation Cancer Project to publicize the support content.

6. Updating the treatment development map:

 We requested the domestic multi-institutional collaborative trial group to update the treatment development map, which lists standard treatments and clinical trial information for 30 types of cancer. In addition, we added cancer pain and cancer treatment-related pain and made them available on the portal site.

Education

 We have trained personnel who can be successful as PMs.

Future Prospects

 In fiscal 2024, we will continue to enhance our support offerings and contribute to accelerating progress on each study of the Innovative Cancer Project.